Skip to content
Head to head

Ironwood Pharmaceuticals vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: IRWD · TAK

Updated 10 minutes ago

1-year performance, rebased to 100

IRWD +50.2%TAK +56.6%
It’s close.
IRWDTAK
Snapshot
SectorDrug Manufacturers - Specialty & Generic--
Last price4.7021.77
Change today-0.21%+1.68%
1-year return+48.3%+57.5%
Market cap$778.09M$69.76B
52-week range2.95 – 5.7813.92 – 22.07
Valuation
P/E (TTM)5.22311.00
P/E percentile, own 5-yr range55th100th
P/B-8.011.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)0.15-0.30
Net profit (TTM)$24.83M$-970.94M
Revenue (TTM)$400.30M$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+9.0%+6.7%
Gross margin100.0%65.8%
Operating margin62.8%14.3%
Net margin37.4%0.9%
Free cash flow (TTM)$205.37M$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership95.8%51.3%
Insider activity (12mo)28 buy / 22 sell19 buy / 31 sell
Short interest (% of float)9.0%0.1%
Analyst consensus100% buy (1)100% buy (1)
Analyst price target$6 (+28%)$50 (+132%)
StockVane view
StockVane Quant RatingC (87)C (90)
Company
Employees10047,029
Founded19981781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.